Literature DB >> 16113300

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system.

Ida Rosenkrands1, Else Marie Agger, Anja W Olsen, Karen S Korsholm, Claire Swetman Andersen, Klaus T Jensen, Peter Andersen.   

Abstract

The immunostimulation provided by the mycobacterial cell wall has been exploited for many decades, e.g., in Freund's complete adjuvant. Recently, the underlying mechanism behind this adjuvant activity, including Toll receptor signaling, has begun to be unraveled, confirming the potential of mycobacterial constituents to act as adjuvants. In this study, the immunostimulatory properties of a Mycobacterium bovis BCG lipid extract were tested for their adjuvant activity. Administration of the lipids in dimethyl dioctadecyl ammonium bromide-based cationic liposomes induced a powerful Th1 response characterized by markedly elevated antigen-specific immunoglobulin G2a (IgG2a) isotype antibodies and substantial production of gamma interferon. The adjuvant formulation (designated mycosomes) elicited high levels of gamma interferon both in C57BL/6 as well as in Th2-prone BALB/c mice. Furthermore, the mycosomes induced immune responses to protein antigens from several sources including Mycobacterium tuberculosis, Chlamydia muridarum, and tetanus toxoid. In a tuberculosis challenge model, the mycosomes combined with the Ag85B-ESAT-6 fusion protein were demonstrated to have a unique ability to maintain sustained immunological memory at a level superior to live BCG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113300      PMCID: PMC1231148          DOI: 10.1128/IAI.73.9.5817-5826.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.

Authors:  L Krishnan; S Sad; G B Patel; G D Sprott
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

3.  Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages.

Authors:  Nasim A Begum; Kazuo Ishii; Mitsue Kurita-Taniguchi; Masako Tanabe; Mika Kobayashi; Yasuhiro Moriwaki; Misako Matsumoto; Yasuo Fukumori; Ichiro Azuma; Kumao Toyoshima; Tsukasa Seya
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

4.  T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis.

Authors:  P Andersen; D Askgaard; L Ljungqvist; M W Bentzon; I Heron
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 6.  Unique immunomodulating properties of dimethyl dioctadecyl ammonium bromide (DDA) in experimental viral vaccines.

Authors:  D Katz; S Lehrer; O Galan; B Lachmi; S Cohen; I Inbar; I Samina; B Peleg; D Heller; H Yadin; D Chai; E Freeman; H Schupper; P Fuchs
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

7.  Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers.

Authors:  B W McBride; A Mogg; J L Telfer; M S Lever; J Miller; P C Turnbull; L Baillie
Journal:  Vaccine       Date:  1998-05       Impact factor: 3.641

8.  Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.

Authors:  Y Koike; Y C Yoo; M Mitobe; T Oka; K Okuma; S Tono-oka; I Azuma
Journal:  Vaccine       Date:  1998-12       Impact factor: 3.641

9.  Proteins released from Mycobacterium tuberculosis during growth.

Authors:  P Andersen; D Askgaard; L Ljungqvist; J Bennedsen; I Heron
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

10.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more
  16 in total

1.  Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection.

Authors:  Else Marie Agger; Joseph P Cassidy; Joseph Brady; Karen S Korsholm; Carina Vingsbo-Lundberg; Peter Andersen
Journal:  Immunology       Date:  2008-01-12       Impact factor: 7.397

2.  Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.

Authors:  Hong Zheng; Yun Hu; Wei Huang; Sabina de Villiers; Paul Pentel; Jianfei Zhang; Harry Dorn; Marion Ehrich; Chenming Zhang
Journal:  J Biomed Nanotechnol       Date:  2015-12       Impact factor: 4.099

3.  The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes.

Authors:  Karen Smith Korsholm; Else Marie Agger; Camilla Foged; Dennis Christensen; Jes Dietrich; Claire Swetman Andersen; Carsten Geisler; Peter Andersen
Journal:  Immunology       Date:  2007-02-14       Impact factor: 7.397

4.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 5.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

6.  Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.

Authors:  Dennis Christensen; Thomas Lindenstrøm; Gijsbert van de Wijdeven; Peter Andersen; Else Marie Agger
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Adjuvants induce distinct immunological phenotypes in a bovine tuberculosis vaccine model.

Authors:  H Martin Vordermeier; Gillian S Dean; Ida Rosenkrands; Else M Agger; Peter Andersen; Daryan A Kaveh; R Glyn Hewinson; Philip J Hogarth
Journal:  Clin Vaccine Immunol       Date:  2009-07-29

8.  Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis.

Authors:  Rajesh Mani; Manish Gupta; Anshu Malik; Ravi Tandon; Rajendra Prasad; Rakesh Bhatnagar; Nirupama Banerjee
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

Review 9.  Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists.

Authors:  Matthew Black; Amanda Trent; Matthew Tirrell; Colleen Olive
Journal:  Expert Rev Vaccines       Date:  2010-02       Impact factor: 5.217

10.  Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis.

Authors:  Reinier Borrero; María de los A García; Liem Canet; Caridad Zayas; Fátima Reyes; Jorge L Prieto; Juan F Infante; María E Lanio; Ramlah Kadir; Yamilé López; María E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  BMC Immunol       Date:  2013-02-25       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.